期刊文献+

黏膜免疫系统和黏膜疫苗 被引量:4

Mucosal immune system and mucosal vaccines
下载PDF
导出
摘要 局部及全身的黏膜免疫反应,特别是黏膜表面的分泌型IgA,对抵御经呼吸道、消化道或泌尿生殖道等黏膜表面入侵的病原体有着非常重要的作用。诱导黏膜免疫应答最有效的方式就是将抗原直接接种到黏膜表面,但是这种直接接种并不容易诱导具有保护效果的免疫应答。到目前为止,仅有少数几种黏膜疫苗获准在人体应用。本文简述了黏膜免疫系统的结构及功能,并对现有的及正在研发中的黏膜疫苗进行了总结概括。 Increasing evidence has suggested that mucosal immune responses, especially secretary IgA (sIgA), play an important role in protection against the entry of pathogens through mucosae surfaces such as the respiratory, gastrointestinal or urogenital mucosae. Mucosal immune responses are the most efficiently induced by the administration of antigens onto mucosal surfaces, but such immunization strategy is not liable to induce systemic and mucosal protective immune responses. As a result, only a few of mucosal vaccines are currently approved for human use. This review aims to provide a brief overview on structure and function of the mucosal immune system and some mucosal vaccines being used and developed nowadays.
出处 《传染病信息》 2010年第6期325-328,共4页 Infectious Disease Information
基金 国家"十一五"科技重大专项(2008ZX10001-011)
关键词 疫苗 黏膜 免疫系统 获得性免疫缺陷综合征 vaccines mucous membrane immune system acquired immunodeficiency syndrome
  • 相关文献

参考文献28

  • 1Holmgren J,Czerkinsky C.Mucosal immunity and vaccines[J].Nat Med,2005,11(4 Suppl):S45-S53.
  • 2Chumakov K,Ehrenfeld E,Wimmer E,et al.Vaccination against polio should not be stopped[J].Nat Rev Microbiol,2007,5(12):952-958.
  • 3Tacket CO,Cohen MB,Wasserman SS,et al.Randomized,doubleblind,placebo-controlled,multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae Ol El tor inaba three months after vaccination[J].Infect Immun,1999,67(12):6341-6345.
  • 4Richie EE,Punjabi NH,Sidharta YY,et al.Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta,Indonesia,a cholera-endemic area[J].Vaccine,2000,18(22):2399-2410.
  • 5Klugman KP,Koornhof HJ,Robbins JB,et al.Immunogenicity,efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization[J].Vaccine,1996,14(5):435-438.
  • 6Yang HH,Wu CG,Xie GZ,et al.Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China[J].Bull World Health Organ,2001,79(7):625-631.
  • 7Levine MM,Ferreccio C,Cryz S,et al.Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial[J].Lancet,1990,336(8720):891-894.
  • 8Levine MM,Ferreccio C,Abrego P,et al.Duration of efficacy of Ty21a,attenuated Salmonella typhi live oral vaccine[J].Vaccine,1999,17(Suppl 2):S22-S27.
  • 9Soares-Weiser K,Maclehose H,Ben-Aharon I,et al.Vaccines for preventing rotavirus diarrhoea:vaccines in use[J].Cochrane Database Syst Rev,2010,(5):CD008521.
  • 10Peter G,Myers MG.Intussusception,rotavirus,and oral vaccines:summary of a workshop[J].Pediatrics,2002,110(6):e67.

二级参考文献30

  • 1Cohen J. HIV/AIDS research. Surprising AIDS vaccine success praised and pondered[J]. Science, 2009, 326(5949):26- 27.
  • 2Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand[EB/OL]. [2009-10-22]. http://content.nejm. org/cgi/content/full/NEJMoa0908492.
  • 3Mulligan MJ. Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions[J]. Curr Infect Dis Rep, 2009, 11(5):399-406.
  • 4Letvin NL. Progress toward an HIV vaccine[J]. Annu Rev Med, 2005, 56:213-223.
  • 5Baroneh DH. Challenges in the development of an HIV-1 vaccine[J]. Nature, 2008, 455(7213):613-619.
  • 6Hu SL. Non-human primate models for AIDS vaccine research[J]. Curr Drug Targets Infect Disord, 2005, 5(2): 193- 201.
  • 7Hatziioannou T, Ambrose Z, Chung NP, et al. A macaque model of HIV-1 infection[J]. Proc Natl Acad Sci U S A, 2009, 106(11):4425 -4429.
  • 8Berman PW, Gregory TJ, Riddle L, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160[J]. Nature, 1990, 345(6276):622-625.
  • 9Berman PW, Murthy KK, Wrin T, et al. Protection of MN-rgp- 120-immunized chimpanzees from heteroiogous infection with a primary isolate of human immunodeficiency virus type I[J]. J Inf Dis, 1996, 173(1):52-59.
  • 10Cohen J. Public health. AIDS vaccine trial produces disap- pointment and confusion[J]. Science, 2003, 299(5611): 1290- 1291.

共引文献1

同被引文献28

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部